ArticleThe oncologist2011
Will imatinib compromise reproductive capacity?
Article in The oncologist, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 71 citations in OpenAlex.
- Impact of immunotherapy and small molecule cancer therapy on fertility: a narrative review of current evidence, mechanisms and future directions.BMJ oncology · 2026Review
- Fertility Protection in Female Cancer Patients: From Molecular Mechanisms of Gonadotoxic Therapies to Pharmacotherapeutic Possibilities.International journal of molecular sciences · 2025Review
- Effect of Imatinib Mesylate on the Ovarian Reserves of Female Patients with Chronic Myeloid Leukaemia.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Management of CML and Pregnancy in Low-and Middle-income Countries.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- Review
- Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.Annals of hematology · 2023Article
- Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies.Reproduction & fertility · 2022Review
- Impact of imatinib administration on the mouse ovarian follicle count and levels of intra-ovarian proteins related to follicular quality.Clinical and experimental reproductive medicine · 2022Article
- Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.Journal of assisted reproduction and genetics · 2021Review
- Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia.Journal of assisted reproduction and genetics · 2020Article
- Long-term imatinib diminishes ovarian reserve and impacts embryo quality.Journal of assisted reproduction and genetics · 2020Article
- Ovarian damage from chemotherapy and current approaches to its protection.Human reproduction update · 2019Review
- Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.The oncologist · 2019Article
- Cancer Treatment-Related Infertility: A Critical Review of the Evidence.JNCI cancer spectrum · 2019Review
- Imatinib treatments have long-term impact on placentation and embryo survival.Scientific reports · 2019Article
- C-Abl is not actıvated in DNA damage-induced and Tap63-mediated oocyte apoptosıs in human ovary.Cell death & disease · 2018Article
- Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
- Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α.The oncologist · 2018Article
- A live birth from vitrified-warmed oocytes in a Philadelphia chromosome-positive acute lymphoid leukemia patient 5 years following allogenic bone marrow transplantation and after a magnitude 9.0 earthquake in Japan.Reproductive medicine and biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conventional gonadotoxic chemotherapeutics, many female patients using imatinib may choose to preserve fertility. Herein, we provide evidence of a potential negative effect of imatinib on ovarian function by reporting the first case of a woman who showed a severely compromised ovarian response to gonadotropin stimulation while on imatinib, with a normal ovarian response after stopping this medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.